Genzyme Corporation to Pay FDA $175M in Settlement

Boston Business Journal -- Drug developer Genzyme Corp. of Cambridge has agreed to pay the Food and Drug Administration $175 million to settle manufacturing enforcement action, the company disclosed in a regulatory filing Wednesday.